Usefulness of Bromocriptine in the Treatment of Amisulpride-induced Hyperprolactinemia

We investigated the effect of bromocriptine on amisulpride-induced endocrinological disturbances (galactorrhea/amenorrhea) and on psychotic symptoms in an open-labeled study. Five women suffering from chronic psychosis and amisulpride-induced hyperprolactinemia (AIH) with amenorrhea and/or galactorrhea received bromocriptine at a dose of 10-40 mg/day. In none of these patients could prolactin levels be reduced to the normal range. They were markedly reduced in three of five patients. Menses recurred in one of four patients with amenorrhea. Lactation decreased in one of three patients with galactorrhea. In two patients with reduced prolactin levels, psychotic symptoms exacerbated but fully remitted after discontinuation of bromocriptine therapy. Thus, bromocriptine seems to annihilate the central effect of amisulpride at a dose that reduces AIH. Therefore, bromocriptine appears not to be suited for the treatment of AIH.